Fexofenadine/Cyclodextrin Inclusion Complexation: Phase Solubility, Thermodynamic, Physicochemical, and Computational Analysis

REFERENCES

• Al Omari M. M., Zughul M. B., Davies J. E. D., Badwan A. A. Sildenafil/cyclodextrin complexation: Stability constants, thermodynamics, and guest-host interaction probed by 1H-NMR and molecular modeling studies. J. Pharm. Biomed. Anal. 2006a; 4: 857–865
   Web of Science ®Google Scholar
• Al Omari M. M., Zughul M. B., Davies J. E. D., Badwan A. A. Effect of buffer species on the inclusion complexation of acidic drug celecoxib with cyclodextrin in solution. J. Incl. Phenom. Macrocyc. Chem. 2006b; 55: 247–254
   Web of Science ®Google Scholar
• Al Omari M. M., Zughul M. B., Davies J. E. D., Badwan A. A. Factors contributing to solubility synergism of some basic drugs with β-cyclodextrin in ternary molecular complexes. J. Incl. Phenom. Macrocyc. Chem. 2006c; 54: 159–164
   Web of Science ®Google Scholar
• Al Omari M. M., Zughul M. B., Davies J. E. D., Badwan A. A. Effect of buffer species on the inclusion complexation of basic drug terfenadine with β-cyclodextrin in solution. J. Incl. Phenom. Macrocyc. Chem. 2007; 58: 227–235
   Web of Science ®Google Scholar
• Backensfeld T., Muller B. W., Kolter K. Interaction of NSA with cyclodextrins and hydroxypropylcyclodextrin derivatives. Int. J. Pharm. 1991; 74: 85–93
   Web of Science ®Google Scholar
• Badwan A. A., Al Omari M. M., Zughul M. B., Davies J. E. D. Highly soluble binary cyclodextrin inclusion complexes. Patent No. EP1570862 A1. Application No. EP 2004–4227 20040225, 2005
   Google Scholar
• Chen F, Patel M. V. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents. Patent No. WO2000059475. Application No. WO2000-US7342 20000316, 2000
   Google Scholar
• Connors K. A. The stability of cyclodextrin complexes in solution. Chem. Rev. 1997; 97: 1325–1358
   PubMed Web of Science ®Google Scholar
• Dresser G. K., Kim R. B., Bailey D. G. Effect of grapefruit juice volume on the reduction of fexofenadine bioavailability: Possible role of organic anion transporting polypeptides. Clin. Pharmacol. Ther. 2005; 77: 170–177
   PubMed Web of Science ®Google Scholar
• El-Barghouthi M. I., Masoud N. A., Al-Kafawein J. K., Zughul M. B., Badwan A. A. Host-guest interactions of risperidone with native and modified cyclodextrins: Phase solubility, thermodynamics and molecular modeling studies. J. Incl. Phenom. Macrocyc. Chem. 2005; 53: 15–22
   Web of Science ®Google Scholar
• Esclusa-Diaz M. T., Gayo-Otero M., Perez-Marcos M. B., Vila-Jato J. L., Torres-Labandeira J. J. Preparation and evaluation of ketoconazole-β-cyclodextrin multicomponent complexes. Int. J. Pharm. 1996; 142: 183–187
   Web of Science ®Google Scholar
• Fexofenadine hydrochloride USP monograph. United States Pharmacopoeia (USP)29th. INC, Maryland 2006; 905–906, USP Convention
   Google Scholar
• Gladys G., Claudia G., Marcela L. The effect of pH and triethanolamine on sulfisoxazole complexation with hydroxypropyl-β-cyclodextrin. Eur. J. Pharm. Sci. 2003; 20: 285–293
   PubMed Web of Science ®Google Scholar
• Henton D. R., Mccarty F. J. Process for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs. Patent No. WO9531437. Application No. PCt/US95/04942, 1995
   Google Scholar
• Higuchi T., Connors K. A. Phase solubility techniques. Advances in analytical chemistry and instrumentation, C. N. Reilley. Wiley-Interscience, New York 1965; Volume 4: 117–212
   Google Scholar
• Illum L., Watts P. J., Cheng Y. Novel formulations of fexofenadine. Patent No. WO2000021510. Application No. WO99-GB3396 19991012, 2000
   Google Scholar
• Kim Y., Oksanen D. A., Massefski W., Blake J. F., Duffy E. M., Chrunyk B. Inclusion complexation of ziprasidone mesylate with β-cyclodextrin sulfobutyl ether. J. Pharm. Sci. 1998; 87: 1560–1567
   PubMed Web of Science ®Google Scholar
• Kumar N., Khanduri C. H, Sharma M. Amorphos form of fexofenadine hydrochloride. Patent No. WO0071124. Application No. PCT/IB00/00708, 2000
   Google Scholar
• Li P., Tabibi S. E., Yalkowsky S. H. Combined effect of complexation and pH on solubilization. J. Pharm. Sci. 1998; 87: 1535–1539
   PubMed Web of Science ®Google Scholar
• Lin H., Yoo J., Roh H., Lee M., Chung S., Shim C., Kim D. Transport of anti-allergic drugs across the passage cultured human nasal epithelial cell monolayer. Eur. J. Pharm. Sci. 2005; 26: 203–210
   PubMed Web of Science ®Google Scholar
• Liu L., Guo Q.-X. The driving forces in the inclusion complexation of cyclodextrins. J. Incl. Phenom. Macrocyc. Chem. 2002; 42: 1–14
   Web of Science ®Google Scholar
• Menard F. A., Dedhiya M. G., Rhodes C. T. Physico-chemical aspects of the complexations of some drugs with cyclodextrins. Drug Dev. Ind. Pharm. 1990; 16: 91–113
   Web of Science ®Google Scholar
• Meyer G. A., Trespidi L. A., Wilson E. S., Clark C. M., Desai A. J., Sancilio F. D. Oral liquid compositions containing polymer- and carbohydrate-based dispersing agents. Patent No. US6365180. Application No. US99–354982 19990716, 2002
   Google Scholar
• Müller B. W., Albers E. Complexation of dihydropyridine derivatives with cyclodextrins and 2-hydropropyl-β-cyclodextrin in solution. Int. J. Pharm. 1992; 79: 273–288
   Web of Science ®Google Scholar
• Nalluri B. N., Chowdary K. P. R., Murthy K. V. R., Hayman A. R., Becket G. Physicochemical characterization and dissolution properties of nimesulide-cyclodextrin binary systems. AAPS PharmSciTech 2003; 4(1), Article 2 (http://www.pharmscitech.org)
   PubMedGoogle Scholar
• Perlovich G. L., Skar M., Bauer-Brandi A. D. Driving forces and the influence of the buffer composition on the complexation reaction between ibuprofen and HPCD. Eur. J. Pharm. Sci. 2003; 20: 197–200
   PubMed Web of Science ®Google Scholar
• Piel G., Pirotte B., Delneuville I., Neven P., Llabres G., Delarge J., Delattre L. Study of the Influence of both cyclodextrins and L-lysine on the aqueous solubility of nimesulide: Isolation and characterization of nimesulide-L-lysine-cyclodextrin complexes. J. Pharm. Sci. 1997; 86: 475–480
   PubMed Web of Science ®Google Scholar
• Ribeiro L., Veiga F. Complexation of vinpocetine with cyclodextrins in the presence or absence of polymers: Binary and ternary complexes preparation and characterization. J. Incl. Phenom. Macrocyc. Chem. 2002; 44: 251–256
   Web of Science ®Google Scholar
• Russell T., Stoltz M., Weir S. Pharmacokinetics, pharmacodynamics, and tolerance of single- and multiple-dose fexofenadine hydrochloride in healthy male volunteers. Clin. Pharmacol. Ther. 1998; 64: 612–621
   PubMed Web of Science ®Google Scholar
• Tannergren C., Petri N., Knutson L., Hedeland M., Lennernas H. Multiple transport mechanisms involved in the intestinal absorption and first-pass extraction of fexofenadine. Clin. Pharmacol. Ther. 2003; 74: 423–436
   PubMed Web of Science ®Google Scholar
• Taraszewska J., Migut K., Kozbiat M. Complexation of flutamide by native and modified cyclodextrins. J. Phys. Org. Chem. 2003; 16: 121–126
   Web of Science ®Google Scholar
• Tinwalla A. Y., Hoesterey B. L., Xiang T., Lim K., Anderson B. D. Solubilization of thiazolobenzimidazole using a combination of pH adjustment and complexation. Pharm. Res. 1993; 10: 1136–1143
   PubMed Web of Science ®Google Scholar
• Ventura C. A., Giannone I., Paolino D., Pistara V., Corsaro A., Puglisi G. Preparation of celecoxib-dimethy-β-cyclodextrin inclusion complex: Characterization and in vitro permeation study. Eur. J. Med. Chem. 2005; 40: 624–631
   PubMed Web of Science ®Google Scholar
• Williams R. O., Johnston K. P., Young T. J., Rogers T. L., Barron M. K., Yu Z., Hu J. Process for production of nanoparticles and microparticles by spray freezing into liquid. Patent No. WO2002060411. Application No. WO2002-US2894 20020130, 2002
   Google Scholar
• Yoshida A, Yamamoto M, Irie T, Hirayama F, Uekama K. Some pharmaceutical properties of 3-hydroxypropyl- and 2,3-dihydroxypropyl-beta-cyclodextrins and their solubilizing and stabilizing abilities. Chem. Pharm. Bull. 1989; 37: 1059–1063
   PubMed Web of Science ®Google Scholar
• Zughul M. B., Badwan A. A. SL2 type phase solubility diagrams, complex formation and chemical speciation of soluble species. J. Incl. Phenom. Macrocyc. Chem. 1998; 31: 243–264
   Web of Science ®Google Scholar